Our study also suggests that HDAC4‐mediated FoxO1 deacetylation could represent a novel target for pharmacotherapy, not only of decreasing glucose‐sensitive insulin secretion but also for insulin resistance. Here, FOXO1 is linked to Insulin resistance.